Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex.

por Rimm, D L, Koslov, E R, Kebriaei, P, Cianci, C D, Morrow, J S
Publicado 1995

Dose intensification of Busulfan in the preparative regimen is associated with improved survival: A Phase I/II Controlled, Randomized Study

por Parmar, S, Rondon, G, deLima, M, Thall, P, Bassett, R, Anderlini, P, Kebriaei, P, Khouri, I, Ganesan, P, Champlin, R, Giralt, S
Publicado 2012

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

por Popat, U, de Lima, MJ, Saliba, RM, Anderlini, P, Andersson, BS, Alousi, AM, Hosing, C, Nieto, Y, Parmar, S, Khouri, IF, Kebriaei, P, Qazilbash, M, Champlin, RE, Giralt, SA
Publicado en Bone Marrow Transplant (2011)

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignanci...

por Kebriaei, P, Madden, T, Kazerooni, R, Wang, X, Thall, P, Ledesma, C, Nieto, Y, shpall, EJ, Hosing, C, Qazilbash, M, Popat, U, Khouri, I, Champlin, RE, Jones, RB, Andersson, BS
Publicado 2010

Intravenous Busulfan Plus Melphalan: An Effective, Chemotherapy-only Transplant Conditioning Regimen in Patients with Acute Lymphoblastic Leukemia

por Kebriaei, P, Madden, T, Wang, X, Thall, PF, Ledesma, C, de Lima, M, Shpall, EJ, Hosing, C, Qazilbash, M, Popat, U, Alousi, A, Nieto, Y, Champlin, RE, Jones, RB, Andersson, BS
Publicado en Bone Marrow Transplant (2012)

Is there an expiration date for a cord blood unit in storage?

por Parmar, S., de Lima, M., Worth, L., Petropoulos, D., Lee, D., Cooper, L., Kongtim, P., Alousi, A., Hosing, C., Popat, U., Kebriaei, P., McNiece, I., Shpall, E., Rondon, G., Champlin, R.
Publicado en Bone Marrow Transplant (2014)

Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantat...

por Kebriaei, P, Basset, Roland, Ledesma, C, Ciurea, S, Parmar, S, Shpall, EJ, Hosing, C, Khouri, Issa, Qazilbash, M, Popat, U, Alousi, A, Nieto, Y, Jones, RB, de Lima, M, Champlin, RE, Andersson, BS
Publicado en Biol Blood Marrow Transplant (2012)

High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin’s lymphoma in patients >65 years of age

por Hosing, C., Saliba, R. M., Okoroji, G.-J., Popat, U., Couriel, D., Ali, T., De Padua Silva, L., Kebriaei, P., Alousi, A., De Lima, M., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R. E., Khouri, I.
Publicado 2008

Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT

por Ciurea, SO, Saliba, R, Rondon, G, Pesoa, S, Cano, P, Fernandez-Vina, M, Qureshi, S, Worth, LL, McMannis, J, Kebriaei, P, Jones, RB, Korbling, M, Qazilbash, M, Shpall, EJ, Giralt, S, de Lima, M, Champlin, RE, Gajewski, J
Publicado 2009

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies

por Nieto, Y, Thall, P, Valdez, B, Andersson, B, Popat, U, Anderlini, P, Shpall, EJ, Bassett, R, Alousi, A, Hosing, C, Kebriaei, P, Qazilbash, M, Gulbis, A, Chancoco, C, Bashir, Q, Ciurea, S, Khouri, I, Parmar, S, Shah, N, Worth, L, Rondon, G, Champlin, R, Jones, RB
Publicado 2012

Clofarabine Plus Busulfan Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-term Study...

por Kebriaei, P., Bassett, R., Lyons, G., Valdez, B., Ledesma, C., Rondon, G., Oran, B., Ciurea, S., Alousi, A., Popat, U., Patel, K., Ahmed, S., Olson, A., Bashir, Q., Shah, N., Jones, R., Marin, D., Rezvani, K., Nieto, Y., Khouri, I., Qazilbash, M., Hosing, C., Shpall, E., Champlin, R.E., Andersson, B. S.
Publicado en Biol Blood Marrow Transplant (2016)

Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas

por Srour, S. A., Singh, H., McCarty, J., de Groot, E., Huls, H., Rondon, G., Qazilbash, M., Ciurea, S., Bardelli, G., Buck, J., Alousi, A., Nieto, Y., Rezvani, K., Marin, D., Popat, U., Hosing, C., Shpall, E. J., Wierda, W. G., Kantarjian, H., Champlin, R. E., Cooper, L. J., Kebriaei, P.
Publicado en Blood (2020)